Subscribe to Journal
Get full journal access for 1 year
only $94.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pal T, Agnese D, Daly M, et al. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics. Genet Med (in press).
Berwick DM, Hackbarth AD. Eliminating waste in US care. JAMA. 2012;307:1513–1516.
U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716–726.
Vourtsis A, Berg WA. Breast density implications and supplemental screening. Eur Radiol. 2019;29:1762–1777.
Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37:453–460.
Robson M, Domchek S. Broad application of multigene panel testing for breast cancer susceptibility—Pandora's box is opening wider. JAMA Oncol. 2019 Oct 3; https://doi.org/10.1001/jamaoncol.2019.4004 [Epub ahead of print].
Robson M, Im S, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533.
Sun L, Brentnall A, Patel S, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol. 2019 Oct 3; https://doi.org/10.1001/jamaoncol.2019.3323 [Epub ahead of print].
Saadatmand S, Geuzinge HA, Rutgers EJT, et al. MRI versus mammography for breast cancer screening in women with familial risk (FaMRsc): a multicentre, randomised, controlled trial. Lancet Oncol. 2019;20:1136–1147.
Lee AJ, Cunningham AP, Tischkowitz M, et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med. 2016;18:1190–1198.
Loveday C, Josephs K, Chubb D, et al. p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer. J Clin Endocrinol Metab. 2018;103:4275–4282.
I would like to thank Payal D. Shah and Katherine L. Nathanson for helpful discussions.
S.M.D. has received honoraria from Clovis, Astra Zeneca, and Bristol Meyers Squibb.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Domchek, S.M. Germline genetic testing for breast cancer: which patients? What genes?. Genet Med (2019). https://doi.org/10.1038/s41436-019-0721-9